198. Meet CagriSema: The GLP1-Amylin New Kid on the Block
The New Kid on the block, coming 2027 (ish?), is CagriSema. Today, I’m giving you a clear, evidence-based introduction.
In this episode, I explain what amylin is, why combining it with semaglutide is a new approach, and what the REDEFINE trials actually showed.
In this episode:
- What amylin is, and how it differs from GLP-1 and GIP
- REDEFINE 1: about 20% average weight loss in people without diabetes
- REDEFINE 2: results in people living with type 2 diabetes
- REDEFINE 4: how CagriSema compared with tirzepatide, and how I interpret it
- Side effects, and practical ways to manage them
- Where approval stands, and why to avoid unapproved sources
Part 2, coming next week, goes inside the brain: what CagriSema does to appetite, cravings and food noise.
Resources:
- Garvey WT et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025.
- Davies MJ et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med. 2025.
- Novo Nordisk company announcement on REDEFINE 4, February 23, 2026.
This episode is for education only and isn't personal medical advice. Please speak with your own healthcare provider.
WORK WITH ME
Ontario-Wide Virtual Obesity Management Clinic
https://www.highmetabolicclinic.com
Join my Weight Loss Coaching Program for women, Best Weight https://www.sashahighmd.com/bestweight
Recover Strong for Binge Eating
https://www.sashahighmd.com/bed
Taking the first step toward weight loss can feel overwhelming — but you don’t have to do it alone. I’ve created a curated list of my podcast episodes to gently guide you as you begin your journey. https://www.sashahighmd.com/podcast-guide
FOLLOW SASHA
Instagram - https://www.instagram.com/sashahighmd/
